Published Date: 06 Mar 2023
In a new study, researchers report the use of inhaled corticosteroids (HFNC) in patients with mild to moderate bronchiolitis...
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
2.
Can Alternating Venetoclax Regimens Improve AML Outcomes?
3.
FDA Approves Hemophilia B Second Gene Therapy.
4.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
5.
Studies point to redlining as a 'perfect storm' for breast cancer
1.
Uncovering Dyscrasia: A Comprehensive Guide to Diagnosis and Treatment
2.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
3.
Unlocking The Power Of Cangrelor To Treat Heart Disease
4.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
5.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation